Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)- September 18-20, 2024 / Copenhagen, Denmark
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Evaluation of the Treatment Response to Cladribine Tablets Using a Transcriptomics and Proteomics Approach in the Cerebrospinal Fluid and Peripheral Blood of People with Multiple Sclerosis.
Wiendl H, et al.
Deep Learning Methods can Predict with High Accuracy Cladribine Tablets Treated Patients who Improve Clinical and Cognitive Disability in 2 Years
Battaglini M, et al.
Real-World Effectiveness and Safety of Cladribine Tablets in Patients with Relapsing MS after Suboptimal Response to Prior Oral or Infusion Disease-Modifying Therapy: 12-Month Interim Analysis from the US-Based Phase 4 MASTER-2 Study
Crayton H, et al.
Cladribine Tablets Reduce Slowly Expanding Lesions in Gray Matter-Driven MRI Phenotype and Active Lesions in All Sustain-Based MRI Phenotypes of MS Patients
De Stefano N, et al.
Low Rate of Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
De Stefano N, et al.
Long-Term Effectiveness of Cladribine Tablets Over 4 Years in Relapsing Multiple Sclerosis: Results from the MAGNIFY-MS Extension Study
De Stefano N, et al.
Reasons for and Safety of Treatment Continuation with Cladribine Tablets (CladT) in Year 5 – First Interim Analysis of the CLIP-5 Study
Korsukewitz C, et al.
Switching Patients with Multiple Sclerosis from Anti-CD20 or S1P Receptor Modulators to Cladribine Tablets in the United States: A Real-World Age-Based Analysis
Kutz C, et al.
Cladribine Tablets Use in People with Multiple Sclerosis up to 4 Years and Beyond Following Treatment Initiation: Results from Multi-Country Patient Support Programmes
Oh J, et al.
Age-Stratified Real-World Outcomes in People with Relapsing Multiple Sclerosis over 50 Years of Age after Switching to Cladribine Tablets from High Efficacy Disease-Modifying Therapies
Okuda D, et al.
Long-Term Effects of Cladribine Tablets Treatment on Cognition, Relapses, MRI and Safety Outcomes in Patients with Relapsing Multiple Sclerosis: 4-Year Results from the CLARIFY-MS Extension Study
Selmaj K, et al.
Safety and Effectiveness of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Trial) – 2-Year Results
Sguigna P, et al.
Real-World Experience with Cladribine Tablets (MAVENCLAD) in the MSBase Registry
Spelman T, et al.
Early Effects of Cladribine Tablets on Immune and Inflammatory Markers in Central and Peripheral Compartments in Relapsing Multiple Sclerosis
Wu G, et al.
Rule-Based Semi-Automated Method to Segment T1 Black Holes on 2D Brain Images in Multiple Sclerosis.
Mattiesing RM, et al.
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: